摘要
Myeloid-derived suppressor cells(MDSCs)constitute a crucial component of the immunosuppressive tumor microenvironment.1 Prostaglandin E2 receptor 4(EP4)is involved in regulating immunosuppressive MDSC differentiation and is emerging as a promising target for cancer immunotherapy.2 No EP4 antagonists have been approved for anti-tumor therapy,underscoring the urgent requirement for the discovery of novel EP4 antagonists.G protein and b-arrestin represent two classical downstream pathways for EP4.The inactivity of G protein and b-arrestin serves as a readout to indicate EP4 antagonism,providing a rationale for establishing EP4 drug screening platforms.
基金
supported by the Shanghai Key Medical Specialty Program(China)(No.ZK2019A03 to Y.W.)
Natural Science Research Funds of Minhang District,Shanghai,China(No.2021MHZ071 to Y.W.)
Scientific Research Project funded by Shanghai Fifth People’s Hospital,Fudan University(No.2020WYZT02 to Y.W.)
the National Natural Science Foundation of China(No.82373237 to B.F.,82172644 to W.Q.L)
ECNU Multifunctional Platform for Innovation(011)
The Instruments Sharing Platform of School of Life Science,East China Normal University.
